User Fee Agreement Opens New Tools to Head Off CRLs: Analysis

FDA’s proposed drug user fee (PDUFA VIII) commitments could give drug and biologics sponsors several new opportunities to address manufacturing facility problems before they delay approvals or result in complete response letters (CRLs), according to an analysis from Arnold & Porter.

The law firm said the proposed “CMC facility lifecycle program” represents a potentially significant development under a formalized FDA-sponsor engagement on manufacturing issues before, during and after application review.

Manufacturing-related deficiencies can lead to CRLs and additional review cycles, and the proposed program is intended to identify and resolve those problems earlier through a risk-based approach, Arnold & Porter attorneys wrote in the firm's new Root Causes newsletter on FDA quality and inspection developments.

Among the most notable changes would be a new CMC facility pre-submission meeting available three to six months before filing an original NDA, BLA or supplement. Such meetings are intended to give sponsors an opportunity to discuss their manufacturing supply chain, dependencies among facilities, risk-mitigation plans and previous inspection history — information FDA could then use in its risk-based facility evaluation.

FDA also proposes post-preapproval inspection and post-prelicense inspection meetings. Those meetings would allow applicants to discuss inspection findings and proposed corrective actions after FDA identifies Form 483 observations that could potentially lead to a CRL. If FDA ultimately issues a CRL because of inspection deficiencies, applicants could request a Type A post-action meeting to discuss what needs to be corrected before the application can be approved.

Another potentially important change would provide sponsors with greater advance notice of inspections. Under the proposed commitments, FDA would notify applicants at least 60 days before — and no later than the midpoint of the review cycle — of a planned facility inspection associated with an original application.

Additionally, FDA plans to issue draft guidance in 2028, addressing facility readiness for preapproval and prelicense inspections, best practices and timelines for meetings surrounding inspections and approval actions, and methods sponsors can use to assess their own facility readiness.

Arnold & Porter noted that the PDUFA proposals are part of a broader FDA effort to change its oversight of pharmaceutical manufacturing. The agency has proposed a new registration framework for distributed manufacturing operations and is planning additional rulemaking addressing advanced, distributed and point-of-care manufacturing. FDA also is considering regulations intended to increase transparency about where active pharmaceutical ingredients and finished dosage forms are manufactured.

Meanwhile, FDA’s planned 10/1 reorganization will make changes to the Office of Inspections and Investigations as the agency seeks a more flexible inspection workforce and increases its use of unannounced foreign inspections, the law firm noted.

Taken together, Arnold & Porter said recent developments reflect FDA’s effort to obtain greater visibility into the pharmaceutical manufacturing supply chain while streamlining and updating its regulatory operations.